|Table of Contents|

Correlation between serum miR-129-5p level and sensitivity of trastuzumab in patients with HER-2 positive advanced breast cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 03
Page:
472-476
Research Field:
Publishing date:

Info

Title:
Correlation between serum miR-129-5p level and sensitivity of trastuzumab in patients with HER-2 positive advanced breast cancer
Author(s):
LU Xiangdong; ZHANG Tingrong; ZHAO Tao
Department of Medical Oncology,Affiliated Jiangyin Hospital of Nantong University,Jiangsu Jiangyin 214400,China.
Keywords:
HER-2 positive advanced breast cancer; miR-129-5p; trastuzumab; sensitivity
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2023.03.015
Abstract:
Objective:To evaluate the predictive value of serum miR-129-5p level for sensitivity of trastuzumab in patients with HER-2 positive advanced breast cancer.Methods：107 patients with HER-2 positive advanced breast cancer were treated with trastuzumab therapy.According to the evaluation criteria of solid tumor efficacy(RECIST 1),the patients were divided into therapy sensitive group(76 cases) and drug resistance group(31 cases).Serum miR-129-5p levels were measured by quantitative real-time PCR before initial therapy and compared with healthy controls.The relationship between different miR-129-5p levels and clinical pathological characters were analyzed.The predictive value and threshold of serum miR-129-5p to trastuzumab therapy sensitivity were determined by receiver operating characteristic(ROC).Results：The serum miR-129-5p level of patients in the trastuzumab sensitive group was significantly lower than that of healthy controls(0.627±0.058 vs 1.027±0.129,P=0.001),while the serum miR-129-5p level of patients in the trastuzumab resistant group was lower than that of patients in the trastuzumab sensitive group(0.276±0.031 vs 0.627±0.058,P=0.002).Serum miR-129-5p level in patients with HER-2 positive advanced breast cancer was not related to age,menstruation,ECOG score and metastasis site,but correlated with histological grade and number of metastatic sites.The miR-129-5p level of patients with I-II grade was lower than that of III grade patients.The miR-129-5p level of patients with one or two metastatic sites was lower than that of three or more metastatic sites(P＜0.05).ROC curve analysis showed that the serum miR-129-5p level had a threshold value of 0.43,sensitivity with 0.89 and specificity with 0.72 for differentiating trastuzumab sensitive and drug-resistant patients,and the proportion of patients with miR-129-5p≤0.43 in the trastuzumab resistant group was significantly higher than that in the trastuzumab sensitive group(71% vs 26.3%,P＜0.05).Conclusion：Serum miR-129-5p level can effectively predict the efficacy of trastuzumab therapy in patients with HER-2 positive advanced breast cancer,and is expected to be an effective biomarker for predicting the efficacy of trastuzumab therapy.

References:

[1]SIEGEL RL,MILLER KD,FUCHS HE，et al.Cancer statistics,2022［J］.CA Cancer J Clin,2022,72(1):7-33.
[2]WAKS AG,WINER EP.Breast cancer treatment:a review［J］.JAMA,2019,321(3):288-300.
[3]SCHETTINI F,PRAT A.Dissecting the biological heterogeneity of HER2-positive breast cancer［J］.Breast,2021,59:339-350.
[4]PELICARIO VARGAS B,SARI MHM,FERREIRA LM.Trastuzumab in breast cancer treatment:the era of biosimilars［J］.Anticancer Agents Med Chem,2022,22(14):2507-2516.
[5]XUE WJ,WANG YX,XIE YW,et al.miRNA-based signature associated with tumor mutational burden in colon adenocarcinoma［J］.Front Oncol,2021,11:634841.
[6]LU XD,MA JJ,CHU JH,et al.miR-129-5p sensitizes the response of Her-2 positive breast cancer to trastuzumab by reducing rps6［J］.Cell Physiol Biochem,2017,44(6):2346-2356.
[7]KANEMARU H,MIZUKAMI Y,KANEKO A,et al.Promising blood-based biomarkers for melanoma:recent progress of liquid biopsy and its future perspectives［J］.Curr Treat Options Oncol,2022,23(4):562-577.
[8]DAVEY MG,DAVIES M,LOWERY AJ,et al.The role of microRNA as clinical biomarkers for breast cancer surgery and treatment［J］.Int J Mol Sci,2021,22(15):8290.
[9]BADR M,SAID H,LOUKA ML,et al.MicroRNA-21 as a predictor and prognostic factor for trastuzumab therapy in human epidermal growth factor receptor 2-positive metastatic breast cancer［J］.J Cell Biochem,2019,120(3):3459-3466.
[10]YE XM,BAI WD,ZHU HY,et al.miR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN［J］.BMB Rep,2014,47(5):268-273.
[11]TANG HL,SONG CL,YE F,et al.miR-200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer［J］.J Cell Mol Med,2019,23(12):8114-8127.
[12]XU S,LI W,WU J,et al.The role of miR-129-5p in cancer:a novel therapeutic target［J］.Curr Mol Pharmacol,2022,15(4):647-657.
[13]LI Q,XU K,TIAN JG,et al.miR-129-5p/DLX1 signalling axis mediates functions of prostate cancer during malignant progression［J］.Andrologia,2021,53(11):e14230.
[14]YU YF,ZUO WS,CAI W,et al.miR-129-5p suppresses cell proliferation of human osteosarcoma cancer by down-regulating LncRNA Lnc712［J］.Cancer Manag Res,2021,13:2259-2264.
[15]WAN P,BAI X,YANG C,et al.miR-129-5p inhibits proliferation,migration and invasion in rectal adenocarcinoma cells through targeting E2F7［J］.J Cell Physiol,2020,235(7-8):5689-5701.
[16]程磊，李旭东，王世波，等.HOTAIRM1靶向miR-129-5p对胶质瘤细胞增殖、迁移、侵袭的影响［J］.现代肿瘤医学，2020,28(13):2209-2215. CHENG L,LI XD,WANG SB,et al.The effect of HOTAIRM1 targeting miR-129-5p on the proliferation，migration and invasion of glioma cells［J］.Modern Oncology,2020,28(13):2209-2215.
[17]WU C,MIAO CQ,TANG QS,et al.miR-129-5p promotes docetaxel resistance in prostate cancer by down-regulating CAMK2N1 expression［J］.J Cell Mol Med,2020,24(3):2098-2108.
[18]YU JP,ZHANG XK,MA YW,et al.miR-129-5p restrains apatinib resistance in human gastric cancer cells via downregulating HOXC10［J］.Cancer Biother Radiopharm,2021,36(1):95-105.

Memo

Memo:
江苏省无锡市卫生健康委员会科技成果和适宜技术推广项目（编号：T202111）;江苏省妇幼保健协会科研项目（编号：FYX201908）;江苏省无锡市卫生健康委员会青年基金（编号：Q201904）
Last Update: 2022-12-30